Sign In
Buy ALT
$2.92
+0.0500 (+1.74%)
At Close: Jun 04, 2026
ALT5 Sigma Integrates Lightning Network with Voltage to Enable Instant Bitcoin Payments
09:00am, Tuesday, 27'th May 2025
LAS VEGAS , May 27, 2025 /PRNewswire/ -- ALT5 Sigma Corporation (the "Company" or "ALT5") (NASDAQ: ALTS) (FRA: 5AR1), a fintech company providing blockchain-powered payment and trading infrastructure
ALT5 Sigma Launches Lightning Network Integration to Power Instant Bitcoin and Tether Payments in Partnership with Voltage
08:30am, Tuesday, 27'th May 2025
Support for Bitcoin and Stablecoins on Lightning Underscores ALT5's Commitment to Scalable, Real-Time Settlement Infrastructure LAS VEGAS, NEVADA / ACCESS Newswire / May 27, 2025 / ALT5 Sigma Corporat
ALT5 Sigma Corporation Announces Record Date for Alyea Therapeutics Corporation Transaction
04:18pm, Wednesday, 21'st May 2025
LAS VEGAS, NEVADA / ACCESS Newswire / May 21, 2025 / ALT5 Sigma Corporation (the "Company" or "ALT5") (NASDAQ:ALTS)(FRA:5AR1), a fintech, providing next generation blockchain-powered technologies for
GAITHERSBURG, Md., May 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometab
Altimmune to Participate at Two Upcoming Investor Conferences
07:30am, Wednesday, 14'th May 2025
GAITHERSBURG, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometab
Altimmune, Inc. (ALT) Q1 2025 Earnings Call Transcript
02:57pm, Tuesday, 13'th May 2025
Altimmune, Inc. (NASDAQ:ALT ) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Lee Roth - President, Burns McClellan, Investor Relations Advisors Vipin Garg - Chief Execut
ALT5 Sigma Reports Record First Quarter 2025 and Announces Acquisition of Mswipe
08:00am, Tuesday, 13'th May 2025
Reports third consecutive record quarter for Fintech segment Mswipe acquisition, expected to close early in Q2, will be immediately accretive upon close to revenue and EBITDA Payment Card offering, al
Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital
07:00am, Tuesday, 13'th May 2025
GAITHERSBURG, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometab
Altimmune Announces First Quarter 2025 Financial Results and Business Update
07:00am, Tuesday, 13'th May 2025
Top-line data from IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) expected in Q2 2025 Phase 2 trials in Alcohol Use Disorder (AUD) and Alcohol Liver Di
ALT5 Sigma Sponsors Consensus 2025, Showcasing Crypto Infrastructure Built for Real-World Finance
05:00pm, Friday, 09'th May 2025
ALT5 Sigma brings regulated rails and next-gen payment infrastructure to the biggest stage in crypto LAS VEGAS, NEVADA / ACCESS Newswire / May 9, 2025 / ALT5 Sigma Corporation (NASDAQ:ALTS)(FRA:5AR1),
How Much Upside is Left in Altimmune (ALT)? Wall Street Analysts Think 285.86%
11:01am, Friday, 09'th May 2025
The mean of analysts' price targets for Altimmune (ALT) points to a 285.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analys
MASH Resolution Index (MASHResInd) model highly predictive of MASH resolution MASH Resolution Index (MASHResInd) model highly predictive of MASH resolution
Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025
07:30am, Tuesday, 06'th May 2025
GAITHERSBURG, Md., May 06, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2025 financial
Altimmune to Present at Upcoming EASL International Liver Congress™ 2025
07:30am, Thursday, 01'st May 2025
GAITHERSBURG, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing next-generation peptide-based therapeutics for liver and c
Altimmune to Participate in the Citizens Life Sciences Conference
07:30am, Wednesday, 30'th Apr 2025
GAITHERSBURG, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that members of the Company's management team will
